Arvinas (ARVN) reported a third-quarter loss of $0.82 per share, 2.5% worse than the -$0.80 consensus. Revenue was just $0.5 million against expectations of $25.9 million, a 98.1% shortfall. Earnings fell 70.8% year over year and revenue dropped 98.8%. The headline looks severe, but it mostly reflects a business model that has already changed. The quarter's real story sits elsewhere: a sharply leaner cost structure and a clinical calendar that now hinges on data the company has not yet shown. A December lymphoma readout sets a modest bar, and the Parkinson's/PSP program keeps sliding further out.

The revenue collapse is mechanical, not operational. A year ago, Arvinas booked $20.6 million under the original vepdegestrant collaboration with Pfizer and a $20.0 million Novartis milestone. The Pfizer deferred revenue was fully recognized in the second quarter, when the Rigel license was signed and produced a one-time $249.7 million figure. That leaves only sales-based Rigel royalties, which delivered a first payment of $0.5 million. The $25.9 million consensus appears to have assumed collaboration or milestone revenue that the new structure did not produce in the quarter. That is a modeling gap more than a deterioration in demand.

The wider per-share loss also deserves scrutiny. The net loss grew to $53.9 million from $35.1 million, but operating spending moved the other way:

• GAAP R&D fell to $46.9 million from $64.7 million, and G&A dropped to $12.6 million from $21.0 million.
• Non-GAAP operating expenses were $53.5 million, down 25% from $71.5 million a year earlier and below $67.3 million in the first quarter.
• R&D has stepped down each quarter this year, from $60.3 million to $52.6 million to $46.9 million.
• The loss widened because roughly $41 million of prior-year revenue disappeared and interest income fell to $5.4 million from $9.0 million.
• A share count about 11% smaller amplified the per-share figure.

Cash stood at $558.9 million, down only about $9 million from June. Management reaffirmed runway into the second half of 2028 for the fourth consecutive call.

The call was mainly about execution, and the pipeline news split in two directions.

• **HPK1 (ARV-6723):** The degrader moved from "enrollment in coming weeks" to dosing patients, with first monotherapy data now guided to 2H27. The call framed pembrolizumab combination dosing as a 1H27 event, while the release says mid-2027. That is a minor discrepancy but worth tracking.
• **SBMA (ARV-027):** Healthy-volunteer data and the start of SBMA patient dosing were both reaffirmed for 1H27.
• **LRRK2 (ARV-102):** The program slipped again. The plan a year ago was a U.S. Phase 1b in 1H26 alongside a potential registrational trial in late 2026. The U.S. clinical hold remains unresolved. The Phase 1b will now run only in the EU and UK, with CTAs starting next month and enrollment beginning in 2027. U.S. sites are deferred until after that trial, and registration is now sequential with no date. Encouraging MDS data, showing oculomotor improvement correlated with reductions in the CSF LRRK2 biomarker, softens but does not offset the extended timeline.

The nearest catalyst is ARV-393's ASH presentation in December, and expectations need calibrating. Management set an informal bar of a response rate above 30% in roughly mid-teens T-cell lymphoma patients. However, most of the data come from sub-efficacious doses with limited durability. Competing BCL6 degraders are already posting response rates above 50% in B-cell disease. Clearing management's bar could support the floated idea of a faster registrational path in T-cell lymphoma, but bears have legitimate ammunition if the comparison becomes cross-trial. Funding is another longer-dated risk: ARV-027's trial extends beyond the cash-guidance window, so additional capital will eventually be needed.

Investor sentiment deteriorated meaningfully into the report, falling from roughly neutral (-0.04) to -0.30. Price action tells the same story:

• At $7.52, shares were down 9.7% from the open after the August report.
• The stock sat 22.3% below its 200-day moving average of $9.68.
• It had slipped 22.8% from the August 25 high of $9.74.
• It remained 11.6% above the 52-week low of $6.74 set on October 14.

The price and AVWAP trend readings remain negative, consistent with a stock that has been sold rather than accumulated since the last report.

The bottom line is that the miss is largely accounting noise from the end of the Pfizer revenue stream. Beneath it, Arvinas is spending less, burning cash slowly and hitting most of its near-term trial milestones. The investment case now rests almost entirely on data: a December BCL6 readout from early doses facing tough competitive comparisons, and a series of 2027 readouts. Meanwhile, ARV-102, once the nearest path to registration, has become a slower, ex-U.S. program. With sentiment soured and shares well below trend, the setup is less about this quarter's numbers than about whether ASH can restore confidence.